Sanofi is shipping BEYFORTUS 50mg and 100mg Injection doses in the U.S. to private healthcare providers and to the Centers for Disease Control and Prevention for its Vaccines for Children program to help ensure the majority of doses are available ahead of RSV season. The US market is anticipated to have enough supply so that every eligible baby born outside of the season will have access to immunization at a regular checkup and those born during the season will have access at birth. BEYFORTUS is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi’s Dupixent Shows Promise for Skin Disease
- Regeneron, Sanofi announce FDA approval of Dupixent for adolescent CRSwNP
- Regeneron and Sanofi report Dupixent trial met primary, key secondary endpoints
- Sanofi price target raised to $64 from $56 at Berenberg
- Nurix Therapeutics price target raised to $30 from $27 at Oppenheimer